CompletedPhase 1

PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers

South Korea18 participantsStarted 2025-03-24

Plain-language summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers

Age range19 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age: 19\~50
✓. Weight: between 50.0 kg\~90.0 kg, Body Mass Index(BMI): 18.0 kg/m\^2 or heavier and below 30.0 kg/m\^2

✕. Medical history- chronic liver disease, acute gout attack, uric acid stone, diabetes, hypertension, hyperlipidemia or lipid abnormality
✕. Clinical examination

Area under the plasma concentration versus time curve (AUC)

Timeframe: 7 days

Peak plasma concentrations (Cmax)

Timeframe: 7 days

NCT IDNCT06665425

SponsorJW Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-05-02